Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134096 | 0.76 | NPC1 (0.48) | — | |
| SCHEMBL12701374 | 0.76 | HTR3A (0.55) | — | |
| SCHEMBL4918026 | 0.74 | P2RX7 (0.55) | P2RX7PDE10A | |
| SCHEMBL17310957 | 0.73 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL7702371 | 0.71 | PDE10A (0.69) | PDE10A | |
| SCHEMBL15134892 | 0.71 | PDE10A (0.69) | PDE10A | |
| SCHEMBL7707796 | 0.71 | PDE10A (0.69) | PDE10A | |
| SCHEMBL15509173 | 0.70 | METAP2 (0.46) | PDE10AMETAP2PRKDC | |
| SCHEMBL15515890 | 0.70 | METAP2 (0.46) | PDE10AMETAP2PRKDC | |
| SCHEMBL15509072 | 0.70 | METAP2 (0.46) | PDE10AMETAP2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885PDE10A 1376/4885METAP2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.